APP and Cognitive impairment: In APP/PS1 transgenic mice, the animal model of Alzheimer’s disease, systemic administration of s-EV derived from hypoxia-preconditioned MSCs reduced cognitive impairment in part by decreasing brain inflammation through the inhibition of astrocytes and microglia activation41,42.